Variant · Snv
EGFR V742A
CI-VAR-00004612Explore in graph →NP_005219.2:p.Val742AlaNM_005228.4:c.2225T>CClinVar 376079 CIViC 1001 rs121913466
Curated evidence
Evidence by cancer (3 items)
Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.
- Source
- CIViC — Clinical Interpretation of Variants in Cancer
- Dataset
- CIViC evidence items
- Version
- civic-2026-09-08
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- expert curation
- License
- CC0 1.0
- PMID
- 19147750
- Run
- ING-CIVIC-20260908-000001
| Molecular profile | Therapy | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| Lung Non-Small Cell Carcinoma2 | ||||||||
| EGFR V742A | Erlotinib | Predictive | D | Supports Sensitivity Response | — | accepted | EID4197In an in vitro study, a Ba/F3 cell line expressing EGFR V742A demonstrated increased sensitivity to erlotinib treatment comparable to Ba/F3 cells expressing a known sensitizing mutation (EGFR L858R). … (full text at CIViC) PMID 19147750 · Kancha et al., 2009 · Open in CIViC | civic |
| EGFR V742A | Gefitinib | Predictive | C | Does Not Support Sensitivity Response | 2 | submitted | EID4214In a study, 1 participant with stage IV adenocarcinoma was sequenced at EGFR exons 18 to 21 and was found to have V742A mutation, and was treated with the 1st generation TKI gefitinib. The patient (M,… (full text at CIViC) PMID 21531810 · Wu et al., 2011 · Open in CIViC | civic |
ClinVar
Clinical significance (0)
ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.
Data not yet available